Oncolytics Biotech Inc T.ONC

Big Pharma seeks long term remission x combining I/O therapy

[Noteable]

November 23, 2023 - Boehringer Ingleheim hopes to achieve its goal of  boosting long-term remission rates among individuals with cancer, which currently only occur in 15% to 20% of patients, by combining complementary immuno-oncology platforms—such as T-cell engagers, oncolytic viruses and cancer vaccines—to expand the benefits of immunotherapy to more patients.

https://www.fiercebiotech.com/biotech/boehringer-builds-out-cancer-capabilities-acquires-swiss-biotech-deal-worth-508m

[Noteable]

... Tecentriq (a PD-L1 inhibitor by Roche) can stop T-cells from switching off — by blocking the PD-1/PD-L1 interaction between a cancer cell and a T-cell. This allows for normal immune action on cancer cells.... https://www-thehindubusinessline-com.cdn.ampproject.org/v/s/www.thehindubusinessline.com/portfolio/big-story/merck-novo-nordisk-gilead-biogen-and-more-here-are-the-investment

[Noteable]

BMS’ solid tumor franchise is heavily focused on immuno-oncology compared with targeted therapies, recently highlighted by the acquisition of KRAS 12C inhibitor from idrug development nnovator Mirati Therapeutics for US$ 5.8 Billion. Krazati in December 2022 won an FDA accelerated approval for previously treated KRAS G12C-mutant NSCLC. https://www.fiercepharma.com/pharma/bristol-myers-buys

[venture009]

ONC needs an AA to get things rolling otherwise the process for a bo or partner will be more difficult. 

[Peladawn]

Venture....ya think?.....hmmmm....maybe that’s why they’re trying to go for the AA

[Noteable]

In November 2023 big pharma companies like Boehringer Ingleheim have indicated that they are seeking to achieve their strategic goals of boosting long-term remission rates among individuals with cancer, which currently only occur in 15% to 20% of patients, by combining complementary immuno-oncology platforms—such as T-cell engagers, oncolytic viruses and cancer vaccines—to expand the benefits of